The intravenous (IV) part of the phase IIb dose-finding PROCEED trial of bocunebart (Lu AG09222) met its primary endpoint in migraine prevention, demonstrating a statistically significant difference ...
From the Department of Bizarre Anomalies: Microsoft has suppressed an unexplained anomaly on its network that was routing traffic destined to example.com—a domain reserved for testing purposes—to a ...
A Canadian who has worked in the gaming industry for over two decades, Beck grew up on games such as Final Fantasy and Super Mario Bros. He specalizes in roleplaying games, but covers titles in almost ...
Researchers from MIT, Northeastern University, and Meta recently released a paper suggesting that large language models (LLMs) similar to those that power ChatGPT may sometimes prioritize sentence ...
NEW ORLEANS, LA—A single subcutaneous injection of a novel, small-molecule glycoprotein IIb/IIIa inhibitor administered at first medical contact in patients with suspected STEMI improves the patency ...
Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
The CELEBRATE trial testing the novel injectable glycoprotein IIb/IIIa inhibitor zalunfiban ( Disaggpro; CeleCor Therapeutics) before hospital admission in STEMI patients has met its primary safety ...
Jake Fillery is an Evergreen Editor for GameRant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...
New research shows lymph nodes aren’t just cancer bystanders, they’re the command centers fueling immune attacks. Surgically removing them along with tumors may weaken treatment, while preserving them ...
What if you could unlock the full power of automation without drowning in complexity? Imagine building workflows that feel intuitive yet handle everything from data processing to AI integration, all ...
The cause of mycosis fungoides is unknown and, with the possible exception of very early stage disease, no cure is available. Fortunately, patients with MF have a number of therapeutic options and ...
Denileukin diftitox (DAB IL-2) is a relatively novel agent for treating mycosis fungoides, and is FDA approved for this indication. DAB IL-2 is a fusion protein made through recombinant technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results